2024-12-17 - Analysis Report
## Teladoc Health Inc. (TDOC) Stock Review

**1. Performance Comparison & Divergence:**

Teladoc Health (TDOC) significantly underperformed the S&P 500 (VOO) over the analyzed period.  The cumulative return for TDOC is -62.88%, while VOO's is 121.73%. This represents a massive divergence of -184.6%, placing it at the 4th percentile (0.4 relative divergence) of the historical maximum/minimum divergence range.

**Company Overview:** Teladoc Health Inc. provides virtual healthcare services, including telehealth consultations and related services.

**2. Recent Price Movement:**

* **Closing Price:** $10.68
* **5-day Moving Average:** $10.496
* **20-day Moving Average:** $10.6615
* **60-day Moving Average:** $9.6038

The price is slightly above both the 5-day and 20-day moving averages, suggesting a short-term uptrend, but still below the 60-day average, indicating a longer-term downtrend.


**3. Technical Indicators & Expected Return:**

* **RSI (33.58):**  Suggests the stock is currently in oversold territory.
* **PPO (-1.24):** Indicates bearish momentum.
* **20-Day Relative Divergence Change (-0.1):** Shows a recent short-term decline in relative performance.
* **Expected Return (0.0%):**  The provided data does not suggest any significant expected return relative to the S&P 500 over the long term (2+ years).  This likely reflects the company's current struggles and uncertain future. The current price of $10.68 doesn't show any evidence of a sudden sharp movement (neither up nor down).


**4. Recent Earnings Analysis:**

The recent earnings reports show a consistent trend of negative EPS and relatively flat revenue.  While revenue remains relatively stable around $0.64-$0.66 billion, EPS has been consistently negative, worsening significantly in Q2 2024 (-$4.92). There is no information provided to compare these figures against expectations.  Overall, the financial performance is concerning and shows deteriorating profitability.

**5. Financial Information Analysis:**

* **Revenue:** Revenue has remained relatively flat, indicating a lack of significant growth.
* **Profit Margin:** Profit margins are high, although the fact this is achieved while showing negative EPS would require further analysis to determine if this metric reflects accounting practices which may be masking deeper issues.
* **Equity & ROE:** Equity has fluctuated, and the return on equity (ROE) has been consistently negative, highlighting significant financial challenges.  The substantial drop in ROE in Q2 2024 is particularly alarming.

**6. News and Recent Issues:**

No specific news or recent market outlook information on Teladoc is provided in the given data set.  Analyst opinions and performance highlights are also missing from the provided context.  More recent data would be necessary to reflect any recent news events.

**7. Overall Analysis:**

TDOC significantly underperformed the S&P 500, showing a substantial and sustained decline.  Technical indicators suggest the stock might be oversold, but fundamental analysis reveals concerning negative EPS, flat revenue, and consistently negative ROE.  The company's financial health is clearly a significant concern.  While the high profit margin might appear positive, the negative EPS casts serious doubt on the sustainability of this figure. Without access to the analysts' opinions and the specifics of the market's general outlook for this type of company, further analysis would be speculative. The lack of recent news also restricts an in depth analysis.  More recent data and context are needed to provide a more comprehensive and accurate assessment.

**8. Conclusion:**

Based solely on the provided data, Teladoc Health (TDOC) presents a high-risk investment. While the RSI indicates potential oversold conditions, the persistent negative EPS and ROE raise significant concerns about the company's long-term viability.  Further research, including analyst ratings and a more in-depth understanding of the current market conditions for telehealth companies, is crucial before considering any investment.  Investors should be prepared for further potential losses.
